EP2416799A4 - PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) - Google Patents

PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1)

Info

Publication number: EP2416799A4
Authority: EP; European Patent Office
Prior art keywords: metalloproteinase; mmp; par; activation
Prior art date: 2009-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP10762578.2A

Other languages

German (de)

French (fr)

Other versions

EP2416799A2 (en

EP2416799B1 (en

Inventor

Athan Kuliopulos

Georgios Koukos

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tufts Medical Center Inc

Original Assignee

Tufts Medical Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-10

Filing date

2010-04-12

Publication date

2013-04-17

2010-04-12 Application filed by Tufts Medical Center Inc filed Critical Tufts Medical Center Inc

2010-04-12 Priority to EP15178959.1A priority Critical patent/EP3061460A1/en

2010-04-12 Priority to EP15185115.1A priority patent/EP2990051B1/en

2012-02-15 Publication of EP2416799A2 publication Critical patent/EP2416799A2/en

2013-04-17 Publication of EP2416799A4 publication Critical patent/EP2416799A4/en

2017-11-01 Application granted granted Critical

2017-11-01 Publication of EP2416799B1 publication Critical patent/EP2416799B1/en

Status Not-in-force legal-status Critical Current

2030-04-12 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Materials Engineering (AREA)
Dermatology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Biophysics (AREA)
Mycology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP10762578.2A 2009-04-10 2010-04-12 Par-1 activation by metalloproteinase-1 (mmp-1) Not-in-force EP2416799B1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP15178959.1A EP3061460A1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15185115.1A EP2990051B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16835309P	2009-04-10	2009-04-10
US16836009P	2009-04-10	2009-04-10
PCT/US2010/030783 WO2010118435A2 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)

Related Child Applications (5)

Application Number	Title	Priority Date	Filing Date
EP15185115.1A Division EP2990051B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15185115.1A Division-Into EP2990051B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15178959.1A Division EP3061460A1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15178959.1A Division-Into EP3061460A1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP16184782.7 Division-Into		2016-08-18

Publications (3)

Publication Number	Publication Date
EP2416799A2 EP2416799A2 (en)	2012-02-15
EP2416799A4 true EP2416799A4 (en)	2013-04-17
EP2416799B1 EP2416799B1 (en)	2017-11-01

Family

ID=42936908

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP10762578.2A Not-in-force EP2416799B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15185115.1A Not-in-force EP2990051B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15178959.1A Withdrawn EP3061460A1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
EP15185115.1A Not-in-force EP2990051B1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)
EP15178959.1A Withdrawn EP3061460A1 (en)	2009-04-10	2010-04-12	Par-1 activation by metalloproteinase-1 (mmp-1)

Country Status (7)

Country	Link
US (3)	US20120121706A1 (en)
EP (3)	EP2416799B1 (en)
JP (1)	JP2012523438A (en)
AU (1)	AU2010233089B2 (en)
CA (1)	CA2758322C (en)
DE (1)	DE202010018378U1 (en)
WO (1)	WO2010118435A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9745347B2 (en)	2010-12-30	2017-08-29	Hadasit Medical Research Services And Development Ltd.	PAR1 and PAR2 c-tail peptides and peptide mimetics
EP2606828B1 (en) *	2011-12-20	2018-04-11	Angioclinic AG	Hyaluronic acid and its use for treating venous insufficiency and varicose veins
EP2681209B1 (en) *	2011-03-02	2018-05-09	Aquilus Pharmaceuticals, Inc	Compounds and methods for the treatment of pain and other disorders
EP3351641A1 (en) *	2011-04-08	2018-07-25	Tufts Medical Center, Inc.	Pepducin design and use
CN104271150A (en)	2012-01-12	2015-01-07	比奥根艾迪克Ma公司	Chimeric factor viii polypeptides and uses thereof
JP6256882B2 (en)	2012-02-15	2018-01-10	アムニクスオペレーティングインコーポレイテッド	Factor VIII composition, and method of making and use of the composition
EP2822577B1 (en)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
WO2013183725A1 (en) *	2012-06-06	2013-12-12	国立大学法人九州大学	Non-human model animal, method for creating non-human model animal, and method for screening antithrombogenic drug
CN104661674A (en)	2012-07-11	2015-05-27	阿穆尼克斯运营公司	Factor VIII complexes with XTEN and von Willebrand Factor protein, and uses thereof
US9789209B2 (en) *	2013-03-14	2017-10-17	The Regents Of The University Of California, Berke	Activatable membrane-interacting peptides and methods of use
EP3013359A4 (en) *	2013-06-28	2017-01-25	Biogen MA Inc.	Thrombin cleavable linker
TW202003554A (en)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	Factor VIII-XTEN fusions and uses thereof
HK1223096A1 (en)	2013-09-25	2017-07-21	Vertex Pharmaceuticals Incorporated	Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
AU2015204646B2 (en)	2014-01-10	2020-08-27	Bioverativ Therapeutics Inc.	Factor VIII chimeric proteins and uses thereof
WO2015107139A1 (en) *	2014-01-17	2015-07-23	Proyecto De Biomedicina Cima, S.L.	Compounds for use as antifibrinolytic agents
US20160000791A1 (en)	2014-07-07	2016-01-07	Mayo Foundation For Medical Education And Research	Par1 modulation to alter myelination
WO2016205062A1 (en) *	2015-06-15	2016-12-22	Shifa Biomedical Corporation	Antithrombotic therapies
CN106551944A (en) *	2015-09-25	2017-04-05	南开大学	Purposes of the Tetracyclines derivative as PAR-1 inhibitor
MX2019006444A (en)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
JP7257333B2 (en) *	2017-12-28	2023-04-13	株式会社カネカ	cell aggregation inhibitor
PL3793588T3 (en)	2018-05-18	2025-09-01	Bioverativ Therapeutics Inc.	Methods of treating hemophilia a
WO2020172113A1 (en) *	2019-02-18	2020-08-27	Lankenau Institute For Medical Research	Scar reducing wound closure materials
US11419809B2 (en)	2019-06-27	2022-08-23	L'oreal	Hair treatment compositions and methods for treating hair
KR102612229B1 (en) *	2021-05-21	2023-12-08	가천대학교 산학협력단	Composition for Inhibiting Oligomerization and Fibrillization of Amyloid Beta Comprising N-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]-L-valine or Pharmaceutically Acceptable Salt Thereof
US20230011767A1 (en) *	2021-07-09	2023-01-12	Boston Scientific Scimed, Inc.	Direct oral anticoagulant-eluting medical device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006126182A2 (en) *	2005-05-24	2006-11-30	Inspire M.D Ltd.	Stent apparatuses for treatment via body lumens and methods of use
WO2008005560A2 (en) *	2006-07-07	2008-01-10	Novacea, Inc.	Prevention of thrombotic disorders with active vitamin d compounds

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2990331A (en)	1956-11-23	1961-06-27	Pfizer & Co C	Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en)	1957-10-29	1961-04-18	Pfizer & Co C	Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en)	1958-12-11	1962-11-06	Pfizer & Co C	Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en)	1962-03-08	1965-01-12	Pfizer & Co C	13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en)	1965-06-08	1969-07-08	American Cyanamid Co	Tetracycline antibiotic compositions for oral use
NL6607516A (en)	1966-05-31	1967-12-01
DE1767891C3 (en)	1968-06-28	1980-10-30	Pfizer	Process for the preparation of aqueous medicinal solutions for parenteral, peroral and local use containing a tetracycline derivative
US3784701A (en)	1970-09-21	1974-01-08	American Cyanamid Co	Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US3957980A (en)	1972-10-26	1976-05-18	Pfizer Inc.	Doxycycline parenteral compositions
DE2442829A1 (en)	1974-09-06	1976-03-18	Merck Patent Gmbh	TETRACYCLIC COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION
US4018889A (en)	1976-01-02	1977-04-19	Pfizer Inc.	Oxytetracycline compositions
US4126680A (en)	1977-04-27	1978-11-21	Pfizer Inc.	Tetracycline antibiotic compositions
FR2530247B1 (en)	1982-07-13	1986-05-16	Sanofi Sa	NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4868103A (en)	1986-02-19	1989-09-19	Enzo Biochem, Inc.	Analyte detection by means of energy transfer
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
FR2623810B2 (en)	1987-02-17	1992-01-24	Sanofi Sa	ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5525348A (en)	1989-11-02	1996-06-11	Sts Biopolymers, Inc.	Coating compositions comprising pharmaceutical agents
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
ES2259800T3 (en)	1990-06-11	2006-10-16	Gilead Sciences, Inc.	PROCEDURES FOR THE USE OF NUCLEIC ACID LINKS.
ES2069833T3 (en)	1990-12-03	1995-05-16	Celltech Ltd	PEPTIDILIC DERIVATIVES.
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
FI101150B (en)	1991-09-09	1998-04-30	Sankyo Co	Process for the preparation of tetrahydrothione nopyridine derivatives useful as a drug
EP0552108B1 (en)	1992-01-17	1999-11-10	Lakowicz, Joseph R.	Energy transfer phase-modulation fluoro-immunoassay
GB9211707D0 (en)	1992-06-03	1992-07-15	Celltech Ltd	Peptidyl derivatives
WO1994010300A1 (en)	1992-10-30	1994-05-11	The General Hospital Corporation	Interaction trap system for isolating novel proteins
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5552419A (en)	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
GB9323165D0 (en)	1993-11-10	1994-01-05	Chiros Ltd	Compounds
CZ288436B6 (en)	1994-10-05	2001-06-13	Darwin Discovery Ltd	Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5789434A (en)	1994-11-15	1998-08-04	Bayer Corporation	Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US6326155B1 (en)	1995-03-20	2001-12-04	Dyax Corp.	Engineering affinity ligands for macromolecules
US5837313A (en)	1995-04-19	1998-11-17	Schneider (Usa) Inc	Drug release stent coating process
FR2779726B1 (en)	1998-06-15	2001-05-18	Sanofi Sa	POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE
US20050020607A1 (en)	1999-05-03	2005-01-27	Newton Roger Schofield	Statin-MMP inhibitor combinations
US6858577B1 (en)	1999-06-29	2005-02-22	Ortho-Mcneil Pharmaceutical, Inc.	Indole peptidomimetics as thrombin receptor antagonists
US7696168B2 (en)	2000-04-21	2010-04-13	Tufts Medical Center, Inc.	G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
EP2348047A1 (en) *	2000-04-21	2011-07-27	New England Medical Center	G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
JP4469467B2 (en) *	2000-06-29	2010-05-26	帝人株式会社	Cell growth inhibitor
AU2001267916B2 (en)	2000-07-06	2004-09-09	Daiichi Sankyo Company, Limited	Hydropyridine derivative acid addition salts
US7186693B2 (en)	2001-08-16	2007-03-06	Kimberly - Clark Worldwide, Inc.	Metalloproteinase inhibitors for wound healing
US20050120392A1 (en)	2002-02-28	2005-06-02	Rubinstein Amy L.	Transgenic zebrafish models for thrombosis
US7438925B2 (en)	2002-08-26	2008-10-21	Biovention Holdings Ltd.	Drug eluting coatings for medical implants
AU2004213050B2 (en) *	2003-02-20	2010-09-09	Proteon Therapeutics, Inc.	Methods for the treatment and prevention of diseases of biological conduits
US20050025705A1 (en)	2003-07-22	2005-02-03	Xinkang Wang	Thrombosis animal models and their use in drug discovery and development
US7550444B2 (en)	2004-03-26	2009-06-23	Surmodics, Inc.	Composition and method for preparing biocompatible surfaces
EP1879552B1 (en)	2005-03-14	2016-02-17	Biotegra, Inc.	Drug delivery compositions comprising a polyelectrolyte complex within a polymeric matrix
US20080214599A1 (en)	2005-08-19	2008-09-04	John Thomas Brandt	Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
US20080125354A1 (en)	2005-11-21	2008-05-29	Florida Atlantic University	Selective inhibition of matrix metalloproteinases
US7888483B2 (en)	2006-07-18	2011-02-15	Irm Llc	Antagonists of protease activated receptor-1 (PAR1)
JP4861115B2 (en) *	2006-09-28	2012-01-25	サントリーホールディングス株式会社	Label, method for producing label, method for stabilizing line peeling strength of label over time, and container
US7838232B2 (en) *	2006-10-19	2010-11-23	Auburn University	CaIDAG-GEF1 gene mutations associated with thrombopathy in canines
US9719191B2 (en)	2006-11-29	2017-08-01	The Research Foundation For The State University Of New York	Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs
US7947447B2 (en)	2007-01-16	2011-05-24	Somalogic, Inc.	Method for generating aptamers with improved off-rates
WO2008118320A1 (en)	2007-03-23	2008-10-02	Schering Corporation	Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
WO2008116468A2 (en) *	2007-03-26	2008-10-02	Dako Denmark A/S	Mhc peptide complexes and uses thereof in infectious diseases
US8383156B2 (en)	2007-04-30	2013-02-26	Cordis Corporation	Coating for a medical device having an anti-thrombotic conjugate
US20090018646A1 (en)	2007-07-10	2009-01-15	Zhao Jonathon Z	Coating Employing an Anti-Thrombotic Conjugate
JP5483023B2 (en) *	2008-03-27	2014-05-07	国立大学法人東北大学	Cancer cell motility and cancer cell invasion inhibitor
WO2010119455A2 (en) *	2009-04-15	2010-10-21	Sun Pharma Advanced Research Company Ltd.	An injectable sustained release pharmaceutical composition

2010
- 2010-04-12 US US13/263,715 patent/US20120121706A1/en not_active Abandoned
- 2010-04-12 EP EP10762578.2A patent/EP2416799B1/en not_active Not-in-force
- 2010-04-12 EP EP15185115.1A patent/EP2990051B1/en not_active Not-in-force
- 2010-04-12 AU AU2010233089A patent/AU2010233089B2/en not_active Ceased
- 2010-04-12 JP JP2012504929A patent/JP2012523438A/en active Pending
- 2010-04-12 EP EP15178959.1A patent/EP3061460A1/en not_active Withdrawn
- 2010-04-12 DE DE202010018378.2U patent/DE202010018378U1/en not_active Expired - Lifetime
- 2010-04-12 WO PCT/US2010/030783 patent/WO2010118435A2/en not_active Ceased
- 2010-04-12 CA CA2758322A patent/CA2758322C/en active Active
2014
- 2014-08-14 US US14/460,353 patent/US9376499B2/en active Active
2016
- 2016-05-26 US US15/165,988 patent/US20170065668A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006126182A2 (en) *	2005-05-24	2006-11-30	Inspire M.D Ltd.	Stent apparatuses for treatment via body lumens and methods of use
WO2008005560A2 (en) *	2006-07-07	2008-01-10	Novacea, Inc.	Prevention of thrombotic disorders with active vitamin d compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENNINGS ET AL: "Thrombin receptor antagonsist (TRA SCH530348) is a selective potent inhibitor of PAR1 activity with predictable phramcokinetics", CIRCULATION, vol. 116, II-674, 2007 - 2007, XP002693183 *

Also Published As

Publication number	Publication date
US9376499B2 (en)	2016-06-28
EP2990051B1 (en)	2016-10-26
EP2416799A2 (en)	2012-02-15
WO2010118435A2 (en)	2010-10-14
JP2012523438A (en)	2012-10-04
EP3061460A1 (en)	2016-08-31
AU2010233089B2 (en)	2016-05-26
EP2990051A1 (en)	2016-03-02
WO2010118435A3 (en)	2011-03-17
US20170065668A1 (en)	2017-03-09
CA2758322C (en)	2019-04-02
DE202010018378U1 (en)	2016-04-07
EP2416799B1 (en)	2017-11-01
CA2758322A1 (en)	2010-10-14
US20150023975A1 (en)	2015-01-22
US20120121706A1 (en)	2012-05-17
AU2010233089A1 (en)	2011-11-03

Legal Events

Date	Code	Title	Description
2012-01-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-02-15	17P	Request for examination filed	Effective date: 20111108
2012-02-15	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-07-18	DAX	Request for extension of the european patent (deleted)
2013-04-10	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/16 20060101AFI20130307BHEP Ipc: A61K 9/00 20060101ALI20130307BHEP Ipc: A61P 7/00 20060101ALI20130307BHEP
2013-04-17	A4	Supplementary search report drawn up and despatched	Effective date: 20130318
2014-04-09	17Q	First examination report despatched	Effective date: 20140310
2015-03-16	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-04-08	INTG	Intention to grant announced	Effective date: 20150316
2015-06-19	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2015-06-26	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2015-07-29	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2015-07-29	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2015-07-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2015-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 738753 Country of ref document: AT Kind code of ref document: T Effective date: 20150815
2015-08-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2015-09-10	APBM	Appeal reference recorded	Free format text: ORIGINAL CODE: EPIDOSNREFNO
2015-09-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602010026251 Country of ref document: DE
2015-09-11	PUAC	Information related to the publication of a b1 document modified or deleted	Free format text: ORIGINAL CODE: 0009299EPPU
2015-09-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PK Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN.
2015-10-14	DB1	Publication of patent cancelled	Effective date: 20150911
2015-10-14	REG	Reference to a national code	Ref country code: NL Ref legal event code: HK Effective date: 20151014
2015-11-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REZ Ref document number: 738753 Country of ref document: AT Kind code of ref document: T Effective date: 20150729
2015-11-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R107 Ref document number: 602010026251 Country of ref document: DE
2016-01-16	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2017-09-29	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2017-09-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2017-11-01	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2017-11-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: DIE ERTEILUNG VOM 29.07.2015 WURDE VOM EPA WIDERRUFEN Ref country code: AT Ref legal event code: REF Ref document number: 738753 Country of ref document: AT Kind code of ref document: T Effective date: 20171115
2017-12-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602010026251 Country of ref document: DE
2018-03-07	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20171101
2018-03-26	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2018-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 738753 Country of ref document: AT Kind code of ref document: T Effective date: 20171101
2018-04-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9
2018-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180201 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180201 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2018-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2018-08-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602010026251 Country of ref document: DE
2018-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2018-09-07	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2018-09-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2018-10-10	26N	No opposition filed	Effective date: 20180802
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2018-12-19	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20160430
2019-01-23	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2019-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180430
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180412
2019-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180412
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2020-05-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100412
2020-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171101 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171101
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180412 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180301
2022-12-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20221017 Year of fee payment: 13
2023-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20221013 Year of fee payment: 13 Ref country code: DE Payment date: 20221031 Year of fee payment: 13
2023-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20221018 Year of fee payment: 13
2023-11-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602010026251 Country of ref document: DE
2023-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2023-12-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20230412
2024-01-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230412
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230412 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231103 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430

Publication	Publication Date	Title
EP2416799A4 (en)	2013-04-17	PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1)
EP2502161A4 (en)	2014-01-22	INTER-LANGUAGE SEARCH OPTIONS
UY3955Q (en)	2010-12-31	BODYWORK
BRPI1010796A2 (en)	2016-04-05	perfume systems
BRPI1006128A2 (en)	2016-11-01	sulfonamide derivatives
EP2239194A4 (en)	2015-12-16	PUSH GENERATOR
BRPI1014603A2 (en)	2016-04-05	piston
EP2439128A4 (en)	2013-10-09	VEHICLE
BR112012014167A2 (en)	2016-05-17	shaver
EP2433729A4 (en)	2014-04-30	JIG
EP2400820A4 (en)	2012-08-15	CHARGE BY SUPPLIERS
FR2952681B1 (en)	2017-10-06	PUSH INVERTER
BRPI1013662A2 (en)	2016-04-26	aluminum alloy
BR112012015279A2 (en)	2017-12-12	eletric toothbrush
PT2507635E (en)	2015-02-24	SERIOUS BIOCHEMICAL BIOCHEMICAL
BRPI1015957A2 (en)	2015-09-01	Chestnut-flavored snack
DK2451354T3 (en)	2014-01-13	Lancet
BRPI1010706A2 (en)	2016-03-15	vehicle
BRPI1015154A2 (en)	2016-04-19	power unit.
FR2947857B1 (en)	2012-03-30	DESHUILEUR ARRANGEMENT
EP2509287A4 (en)	2014-11-05	SLIDING-INCLINATION MECHANISM
BRPI1013966A2 (en)	2016-08-09	rapid sterility microassay.
BRPI0907543A2 (en)	2015-07-28	Shaver
FR2947235B1 (en)	2015-12-04	CONNECTING ARRANGEMENT
DK2408659T3 (en)	2013-06-03	Push for bicycles